Curevac B.V. Stock Price, News & Analysis

CureVac (NASDAQ:CVAC) announced the successful closing of a $250 million follow-on public offering, comprising 27,027,028 common shares sold at a price of $9.25 each. The offering was facilitated by major financial institutions including Goldman Sachs, Jefferies, and SVB Securities. The proceeds are intended to support the company's mRNA technology initiatives, which include vaccines for infectious diseases and therapies for various conditions. CureVac’s innovative approach positions it well within the biopharmaceutical landscape, emphasizing its commitment to enhancing patient care through advanced mRNA solutions.

CureVac N.V. (NASDAQ:CVAC) announced a proposed public offering of $200 million of its common shares, with the option for underwriters to purchase up to 15% more within 30 days. The offering will be conducted under an automatically effective shelf registration statement filed with the SEC. Bookrunners include Goldman Sachs, Jefferies, and SVB Securities. CureVac specializes in mRNA technology, with plans for further product development, including COVID-19 vaccines in collaboration with GSK. The actual size and terms of the offering are subject to market conditions.

CureVac N.V. (Nasdaq: CVAC) announced the appointment of Myriam Mendila as Chief Development Officer. With over 20 years of experience in global product development, particularly in oncology, Mendila's expertise is expected to strengthen CureVac's mRNA product pipeline. CEO Franz-Werner Haas emphasized her role at this critical juncture for the company, especially following recent positive data updates from COVID-19 and flu programs. Mendila held significant positions at Roche, Genentech, and Novartis, contributing to her strong background in pharmaceutical development. CureVac continues to focus on advancing its clinical pipeline in various therapeutic areas.

CureVac N.V. (Nasdaq:CVAC) announced promising preliminary data from Phase 1 clinical studies focusing on older adults in COVID-19 and seasonal flu programs. In the COVID-19 program, the monovalent mRNA vaccine, CV0501, demonstrated significant neutralizing antibody titers against the BA.1 variant in individuals aged 65 and older. The flu candidate, Flu-SV-mRNA, showed antibody levels approximately 2.3 times higher than those elicited by the licensed vaccine in adults aged 60-80. Both candidates are set for further clinical development stages in collaboration with GSK in 2023.

CureVac N.V. (NASDAQ:CVAC) announced Dr. Franz-Werner Haas will step down as CEO on March 31, 2023, after a decade with the company. Dr. Alexander Zehnder will succeed him from April 1, 2023, bringing extensive experience from roles at Sanofi and Roche. The transition reflects an important phase for CureVac, especially following recent clinical validation of its mRNA technology platform, aiming to establish the company as a commercial player. The leadership change is expected to have significant implications for the company's strategic direction and market positioning.

CureVac (Nasdaq: CVAC) announced positive preliminary data from ongoing Phase 1 studies of its modified mRNA vaccine candidates for COVID-19 and flu. The candidates utilize CureVac's advanced second-generation mRNA backbone which enhances immune responses at lower doses. The COVID-19 monovalent candidate CV0501 showed strong antibody responses against the Omicron variant BA.1, while the flu vaccine candidate Flu-SV-mRNA also demonstrated robust immunogenicity comparable to a licensed vaccine. CureVac plans to advance both candidates to subsequent clinical phases in 2023.

CureVac N.V. (NASDAQ:CVAC) announced the sale of 103,775 common shares by CEO Franz-Werner Haas, CFO Pierre Kemula, and Interim CDO Ulrike Gnad-Vogt. The sales were conducted solely to meet tax and social security liabilities from a legacy Virtual Stock Option Plan. Management clarified that they do not plan any additional share sales in the near future. Established in Tübingen, Germany, CureVac specializes in mRNA technology and has over 20 years of experience in developing therapeutic solutions.

CureVac (Nasdaq: CVAC) reported third-quarter 2022 revenues of €11.2 million, down 62% year-over-year, primarily due to the terminated collaboration with Boehringer Ingelheim. The company continues to progress its second-generation mRNA vaccine candidates in collaboration with GSK, with four Phase 1 trials underway and results expected in Q1 2023. Operating losses decreased to €52.4 million, while cash reserves stood at €540.9 million. CureVac plans to broaden its oncology initiatives with two proof-of-principle studies set to start in 2023, aiming to enhance its mRNA technology applications in cancer treatment.